KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Shares Issued (2018 - 2025)

Moderna (MRNA) has disclosed Shares Issued for 8 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 45.45% to $16.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.0 million, a 46.97% decrease, with the full-year FY2025 number at $35.0 million, down 46.97% from a year prior.
  • Shares Issued was $16.0 million for Q4 2025 at Moderna, up from $2.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $36.0 million in Q2 2021 to a low of $2.0 million in Q3 2025.
  • A 5-year average of $16.8 million and a median of $15.0 million in 2023 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 101.86% in 2021; the steepest drop was 98.37% in 2021.
  • Moderna's Shares Issued stood at $28.0 million in 2021, then decreased by 10.71% to $25.0 million in 2022, then crashed by 40.0% to $15.0 million in 2023, then fell by 26.67% to $11.0 million in 2024, then skyrocketed by 45.45% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Shares Issued are $16.0 million (Q4 2025), $2.0 million (Q3 2025), and $14.0 million (Q2 2025).